Phyllantus niruri mother tincture in non alcoholic fatty liver disease
- Conditions
- Health Condition 1: K77- Liver disorders in diseases classified elsewhere
- Registration Number
- CTRI/2022/07/044256
- Lead Sponsor
- Dr Amit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Age: 18-60 years ii. Self reported cases of non-alcoholic fatty liver disease. iii. Patients with type 2 diabetes mellitus and dyslipidemia. iv. Patients with BMI more than 25kg/m2.
v. Patients having Alanine aminotransferase (ALT) >40 U/L and Aspartate aminotransferase (AST)/ALT ratio >0.8 to < 1. vi. Ultrasound abdomen showing fatty liver. vii. Non alcoholics or consumption of less than 20 gm and 30 gm of alcohol per day in women and men respectively. viii. Both sexes. ix. Patients volunteering
Patients unwilling to take part or not giving consent to join the study. ii. Diagnosed cases of systemic diseases, psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any organ failure. iii. Known cases of endocrine disorders including Cushingâ??s syndrome or history of long term steroid intake or any other secondary causes of fatty liver. iv. Pregnancy and lactation. v. Substance abuse and/ or dependence. vi. Self reported immune-compromised state. vii. Undergoing homoeopathic treatment for any chronic disease within the last 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Resolution of fatty liver on USG abdomen. ii. Improvement in liver enzymes (AST, ALT).Timepoint: All the outcome measures will be assessed at Baseline (0 month) and after 3 months. <br/ ><br>
- Secondary Outcome Measures
Name Time Method 36-Item Short-Form Health Survey (SF-36). ii. Change in body mass index. <br/ ><br>Timepoint: All the outcome measures will be assessed at Baseline (0 month) and after 3 months. <br/ ><br>